Insights / Latest News

Your patients matter. Your clinical research is invaluable. What you get: 🎯 Matched study opportunities aligned with your real capabilities 🤝 Trusted peer exchange — no noise, no hidden agendas 🧠 Direct access to experienced site experts 📈 Structured training to improve performance and enrollment But here is where it becomes strategically relevant: Through integration with SynapCon’s Site Selection & Feasibility Intelligence, Nexus moves beyond networking — into data-driv

In the fast-paced world of clinical trials, efficiency and compliance are paramount. I have seen firsthand how delays and costs can stall the development of life-saving therapies. That is why I am excited to share the features of Synapcon, a digital platform designed to transform clinical trials. It accelerates processes, cuts expenses, and ensures global regulatory compliance. This platform is a game-changer for biotech, MedTech, pharma companies, CROs, and investigators. Ke

And How a Growing Global Feasibility Network Changes That Clinical trials rarely fail because of science. They fail because of unrealistic feasibility assumptions. Overestimated recruitment. Under performing sites. Delayed activation. Amendments that drain budgets. And every month lost is lost patent lifetime. The Real Risk: Poor Site Selection Sponsors and CROs still rely heavily on: Historical relationships Email-based feasibility surveys Self-reported recruitment optimism

Certified under the German Research Allowance Act (FZulG) for AI and blockchain-enabled clinical trial infrastructure. Announcement SynapCon GmbH has received official certification under the German Research Allowance Act (FZulG), issued by the German federal certification authority. The certified R&D project covers a total eligible development volume of approximately €5.8 million. The project “BC+KI4CTMS” focuses on the development and validation of a next-generation Clinica